Literature DB >> 12062273

Adenoviral gene transfer to the heart during cardiopulmonary bypass: effect of myocardial protection technique on transgene expression.

J M Jones1, K H Wilson, W J Koch, C A Milano.   

Abstract

OBJECTIVE: Adenoviral gene transfer to the arrested heart during cardiopulmonary bypass (CPB) is a novel method of allowing prolonged vector contact with the myocardium. In this model we investigated the importance of temperature, duration of arrest and cardioplegia on transgene expression.
METHODS: First-generation adenoviral vector (1 x 10(12) total viral particles) containing the transgene for the human beta2-adrenoceptor (Adeno-beta(2)AR) or beta-galactosidase (Adeno-beta(gal)) was delivered to neonatal piglets via the proximal aorta, during simulated cardiac surgery, and allowed to dwell for the cross-clamp duration. Four treatment groups received Adeno-beta(2)AR. Groups A (n=4) and B (n=6) underwent cold crystalloid cardioplegia arrest for 10 and 30 min, respectively, Group C (n=5) underwent warm crystalloid cardioplegia arrest for 10 min, and Group D (n=5) underwent warm fibrillatory arrest for 10 min. Group E (n=6) received Adeno-beta(gal) and underwent cold crystalloid cardioplegia arrest (30 min). Animals were weaned off CPB and recovered for 2 days. Receptor density was assessed in membrane fractions using radioligand binding and compared using the Mann-Whitney U-test.
RESULTS: Left ventricular transgene overexpression, as evidenced by elevated betaAR density, following Adeno-beta(2)AR treatment was greatest with cold cardioplegia (Group A 588+/-288.8 fmol/mg; P=0.002 and Group B 520+/-250.9 fmol/mg; P=0.01) versus control (Group E 109+/-8.4 fmol/mg). Overexpression also occurred with warm cardioplegia (Group C 274+/-69.5 fmol/mg; P=0.05) and ventricular fibrillation (Group D 215+/-48.4 fmol/mg; P=0.02) versus control. Comparison of the combined cold cardioplegia groups versus those treated with warm conditions showed a trend towards increased expression with cold conditions (P=0.1). Receptor density was also significantly increased in the right ventricle of animals in Group B (165+/-18.1 fmol/mg; P=0.03) and Group D (181+/-23.4 fmol/mg; P=0.02) versus control (Group E 118+/-5.8 fmol/mg).
CONCLUSIONS: Cold crystalloid cardioplegia is not detrimental to gene transfer in vivo. In fact, there was a trend towards increased left ventricular transgene expression when the adenoviral vector was delivered following cold versus warm cardioplegia. Shorter periods of contact with the vector may reduce transgene overexpression. Therefore, gene transfer is possible during cardiac surgery with clinically used myocardial protection techniques.

Entities:  

Mesh:

Year:  2002        PMID: 12062273     DOI: 10.1016/s1010-7940(02)00078-7

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  9 in total

Review 1.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 2.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

3.  Technique of Complete Heart Isolation with Continuous Cardiac Perfusion During Cardiopulmonary Bypass: New Opportunities for Gene Therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Charles Yarnall; Angel Perez; Alice Isidro; Roger J Hajjar; Charles R Bridges
Journal:  J Extra Corpor Technol       Date:  2018-09

4.  Gene therapy during cardiac surgery: role of surgical technique to minimize collateral organ gene expression.

Authors:  Michael G Katz; JaBaris D Swain; Anthony S Fargnoli; Charles R Bridges
Journal:  Interact Cardiovasc Thorac Surg       Date:  2010-09-22

Review 5.  Current strategies for myocardial gene delivery.

Authors:  Michael G Katz; JaBaris D Swain; Catherine E Tomasulo; Marina Sumaroka; Anthony Fargnoli; Charles R Bridges
Journal:  J Mol Cell Cardiol       Date:  2010-09-15       Impact factor: 5.000

6.  Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences.

Authors:  Qianhong Li; Yiru Guo; Qinghui Ou; Wen-Jian Wu; Ning Chen; Xiaoping Zhu; Wei Tan; Fangping Yuan; Buddhadeb Dawn; Li Luo; Gregory N Hunt; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2011-07-22       Impact factor: 17.165

7.  Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.

Authors:  Qianhong Li; Yiru Guo; Wen-Jian Wu; Qinghui Ou; Xiaoping Zhu; Wei Tan; Fangping Yuan; Ning Chen; Buddhadeb Dawn; Li Luo; Erin O'Brien; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2011-07-21       Impact factor: 17.165

8.  Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Benjamin Brainard; Stephen Cole; Nicholas Russell; Elanor Withnall; Jason Arndt; Caryn Reynolds; Ellen Davison; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H L Sweeney
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

9.  A novel survival model of cardioplegic arrest and cardiopulmonary bypass in rats: a methodology paper.

Authors:  Fellery de Lange; Kenji Yoshitani; Mihai V Podgoreanu; Hilary P Grocott; G Burkhard Mackensen
Journal:  J Cardiothorac Surg       Date:  2008-08-19       Impact factor: 1.637

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.